Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75771 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-18

Study Completion Date

2023-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma

NCT04920162

Melanoma and Vitiligo

COMPLETED NA

Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.

NCT06994208

Melanoma of Skin

RECRUITING

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

NCT03199846

Melanoma

COMPLETED

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

NCT05426239

Advanced Melanoma

COMPLETED

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689

Melanoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For the primary analysis, this study examines the risk of melanoma and nonmelanoma skin cancers: squamous cell carcinoma and basal cell carcinoma in people diagnosed with vitiligo. It also examines actinic keratoses. In secondary analysis, this study examines the prevalence of skin cancer in people diagnosed with vitiligo compared to matched controls.

This study also examines whether the susceptibility to melanoma and nonmelanoma skin cancer may vary between different patient subgroups, e.g. ethnicity, those who undergo phototherapy or treatment with the new targeted biologic immunosuppressive therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo Melanoma (Skin) Nonmelanoma Skin Cancer Squamous Cell Carcinoma Basal Cell Carcinoma Actinic Keratoses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.

Exposure of skin cancer of interest

Intervention Type OTHER

Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.

Controls

The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.

Exposure of skin cancer of interest

Intervention Type OTHER

Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exposure of skin cancer of interest

Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All eligible adult patients (aged ≥ 18) registered with General Practioner (GP) practices contributing data to OPCRD between January 1, 2010 and December 31, 2020, were eligible for inclusion in the study. People diagnosed with vitiligo prior to the study period (prevalent vitiligo) and people newly diagnosed with vitiligo during the study period (incident vitiligo) are included as cases.

Exclusion Criteria

* People actively registered with the GP practice at that date without a history of vitiligo require a minimum one-year registration with their GP practice.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No